2月10日，摩根大通增持澜起科技(06809)113.246万股，每股作价177.6932港元，总金额约为2.01亿港 元。增持后最新持股数目约为861.52万股，最新持股比例为13.07%。 智通财经APP获悉，香港联交所最新资料显示，2月13日，澜起科技(06809)股东将股票存入华泰香港， 存仓市值18.02亿港元，占比13.04%。 ...

2月10日，摩根大通增持澜起科技(06809)113.246万股，每股作价177.6932港元，总金额约为2.01亿港 元。增持后最新持股数目约为861.52万股，最新持股比例为13.07%。 香港联交所最新资料显示，2月13日，澜起科技(06809)股东将股票存入华泰香港，存仓市值18.02亿港 元，占比13.04%。 来源：智通财经网 ...

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Group 1 - The Hong Kong IPO market is experiencing a "dual increase" in both quality and quantity, with a strong preference for globally competitive "Chinese champion" companies [1][2] - The trend of "China for global" is gaining recognition among international investors, leading to a diverse range of companies seeking to list in Hong Kong for international business expansion [2][3] - The active IPO market is expected to enhance liquidity, which in turn can positively impact valuations, creating a virtuous "flywheel effect" [1][5] Group 2 - The shift in motivations for companies going public has evolved, with many now viewing listing in Hong Kong as a strategic step for internationalization rather than just a means of raising funds [2][3] - Regulatory support from both the Chinese and Hong Kong authorities has facilitated the listing process for high-quality A-share companies, encouraging them to seek international capital markets [2][5] - The anticipated IPO market in 2026 is expected to remain active, driven by an increase in listings from quality A-share companies and emerging sectors like AI and semiconductors [3][5] Group 3 - International investors are increasingly recognizing the value of Chinese companies, particularly those in manufacturing and high-growth sectors such as semiconductors and AI [6] - The presence of international cornerstone investors in recent IPOs indicates a growing confidence in the Hong Kong market and Chinese companies [5][6] - The Hong Kong market offers significant long-term value for companies, providing efficient capital-raising opportunities and facilitating rapid growth through streamlined refinancing processes [6]

责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新资料显示，2月10日，摩根大通增持澜起科技（06809）113.246万股，每股作价177.6932 港元，总金额约为2.01亿港元。增持后最新持股数目约为861.52万股，最新持股比例为13.07%。 香港联交所最新资料显示，2月10日，摩根大通增持澜起科技（06809）113.246万股，每股作价177.6932 港元，总金额约为2.01亿港元。增持后最新持股数目约为861.52万股，最新持股比例为13.07%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 ...

证券日报网讯2月13日，澜起科技在互动平台回答投资者提问时表示，DRAM内存模组(如RDIMM和 MRDIMM)属于服务器主内存，与HBM的应用场景不同，分别有相对独立的市场空间，二者都将受益于 AI产业的发展，并非竞争或替代关系。公司经营情况正常。 ...

智通财经APP获悉，香港联交所最新资料显示，2月10日，摩根大通增持澜起科技(06809)113.246万股， 每股作价177.6932港元，总金额约为2.01亿港元。增持后最新持股数目约为861.52万股，最新持股比例 为13.07%。 ...

智通财经APP获悉，香港联交所最新资料显示，2月10日，摩根大通增持澜起科技(06809)113.246万股， 每股作价177.6932港元，总金额约为2.01亿港元。增持后最新持股数目约为861.52万股，最新持股比例 为13.07%。 ...

（原标题：澜起科技(06809)因超额配股权获悉数行使而发行988.35万股） 智通财经APP讯，澜起科技(06809)发布公告，于2026年2月13日因超额配股权获悉数行使而发行及配发 988.35万股H股。 fund ...

澜起科技(06809)发布公告，于2026年2月13日因超额配股权获悉数行使而发行及配发988.35万股H股。 ...